How Modern Drug Delivery Systems Are Changing the Way We Treat Disease

The history of pharmacology is, in large part, a history of delivery problems. Researchers have known for decades what molecules can do in a test tube or a cell culture dish. The harder question – the one that determines whether a promising compound becomes a medicine – is how to get it to the right place in the body, in the right concentration, without causing unacceptable harm along the way.

That question is now being answered at a pace that is visibly changing clinical outcomes across multiple disease areas. The advances driving this change are not primarily in the discovery of new molecules. They are in the science and engineering of how those molecules are packaged, protected, targeted, and released. Drug delivery systems have moved from a supporting role in pharmaceutical development to one of its central disciplines.

The problem that delivery science exists to solve

A therapeutic molecule administered to a patient faces a series of obstacles before it reaches its target. It may be degraded by enzymes in the gastrointestinal tract or bloodstream. It may be too large, too hydrophobic, or too hydrophilic to cross the relevant biological membranes. It may distribute non-specifically throughout the body, reaching healthy tissues and causing toxicity before it reaches the site of disease in meaningful concentration. And if it does reach the target, it may be cleared too rapidly to exert a sustained therapeutic effect.

Conventional formulation – dissolving a drug in water, suspending it in a tablet, or mixing it with excipients in a capsule – addresses some of these problems for some molecules. For the expanding class of therapeutics that are fragile, highly potent, or specifically targeted, conventional formulation is not sufficient.

This is the problem that modern drug delivery systems address. Not by changing the therapeutic molecule, but by engineering the environment in which it travels through the body.

Lipid-based systems: from the first liposome to the mRNA vaccine

The foundational insight of lipid-based drug delivery is that the same phospholipid bilayer structure that forms the membrane of every living cell can be reassembled in the laboratory into a vehicle for delivering molecules. Liposomes – spherical vesicles with a lipid bilayer shell – were first described by Alec Bangham in 1965. The observation that these structures could encapsulate aqueous and hydrophobic compounds alike, and that they were biocompatible and biodegradable, established the conceptual basis for an entire field.

The path from that first observation to clinical application took three decades. Doxil, a liposomal formulation of doxorubicin for ovarian cancer, received FDA approval in 1995 – the first approved nanomedicine. It demonstrated what lipid encapsulation could do in practice: by encapsulating a highly toxic chemotherapy drug in a liposome, researchers extended its circulation time through the enhanced permeability and retention (EPR) effect, increased accumulation in tumour tissue, and substantially reduced cardiotoxicity compared to the free drug. The molecule was unchanged. The delivery system transformed its clinical profile.

The 2020 authorisation of the Pfizer-BioNTech and Moderna mRNA COVID-19 vaccines represented the second pivotal moment. Both vaccines used lipid nanoparticles – LNPs – as delivery systems for mRNA encoding the SARS-CoV-2 spike protein. LNPs solved a problem that had blocked mRNA therapeutics for decades: naked mRNA is rapidly degraded by nucleases in biological fluids and cannot independently cross cell membranes. The LNP protects the mRNA, facilitates cellular uptake via endocytosis, and – critically – enables endosomal escape: the release of the mRNA payload into the cytoplasm where it can be translated into protein.

The speed and scale at which these vaccines were developed and deployed demonstrated something important beyond their immediate public health impact. It validated LNP technology as a production-ready platform capable of operating under regulatory scrutiny at global scale. The pipeline of RNA-based therapeutics that has followed is a direct consequence of that validation.

What lipid nanoparticles make possible that wasn’t possible before

LNP technology has not simply made existing drug classes work better. It has enabled an entirely new category of therapeutics: molecules that program cellular machinery rather than inhibiting or activating receptors.

mRNA therapeutics deliver the genetic instructions to produce a specific protein. The application space extends far beyond vaccines: mRNA encoding a missing or defective protein can in principle substitute for gene replacement therapy in inherited diseases; mRNA encoding tumour antigens can personalise cancer vaccines; mRNA encoding broadly neutralising antibodies can replace repeated protein infusions. Each of these applications depends on delivery – on getting sufficient mRNA into the right cell type to produce the required protein at therapeutic levels.

siRNA and antisense oligonucleotides (ASOs) work by silencing specific genes – directing the cell to destroy or ignore mRNA for a target protein. Several approved siRNA products use LNP or lipid conjugate delivery. Patisiran, an LNP-delivered siRNA for hereditary transthyretin-mediated amyloidosis, was the first approved RNA interference therapeutic and demonstrated that hepatic gene silencing through LNP delivery could be clinically safe and efficacious.

DNA-based gene therapies face delivery challenges analogous to RNA but with additional complexity: DNA must reach the nucleus, not just the cytoplasm. Lipid-based systems for DNA delivery remain an active area of development, complementing viral vector approaches with a non-immunogenic alternative.

The modularity of LNP systems – the ability to alter lipid composition, particle size, surface charge, and surface chemistry independently of each other – makes them unusually adaptable. The same platform technology can be tuned for liver targeting, for inhalation delivery to the lung, for intravenous administration to oncology targets, or potentially for crossing the blood-brain barrier. Each application requires specific optimisation, but the underlying platform is transferable in a way that molecule-specific delivery systems are not.

Beyond LNPs: the broader landscape of advanced delivery systems

Lipid nanoparticles receive the majority of attention, partly because of the mRNA vaccine precedent and partly because the RNA therapeutics pipeline is large and well-funded. But the broader field of lipid-based and nanoparticle drug delivery encompasses several other systems with distinct clinical applications.

Classical liposomes remain the workhorses of lipid-based oncology drug delivery. Multiple approved products – liposomal doxorubicin, liposomal vincristine, liposomal cytarabine – use liposomal encapsulation to improve the therapeutic index of cytotoxic drugs by altering their distribution and reducing off-target toxicity. Surface modification with polyethylene glycol (PEGylation) extends circulation time by reducing macrophage clearance. Active targeting through attachment of antibodies, aptamers, or peptides to the liposome surface directs accumulation to specific cell types or tissues.

Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) offer improved physical and chemical stability over liquid lipid systems, making them particularly suited to hydrophobic drugs with stability challenges. Their solid matrix slows drug release, enabling sustained-release formulations that reduce dosing frequency. They are being investigated for oral, topical, and parenteral delivery of small molecules that are poorly bioavailable in conventional formulations.

Nanoemulsions and self-emulsifying drug delivery systems (SEDDS) address a persistent challenge in oral drug development: the large proportion of small molecule drug candidates that are poorly water-soluble (BCS Class II and IV compounds) and therefore show variable and incomplete oral absorption. Nanoemulsions present the drug in a pre-solubilised form that bypasses the dissolution step in the gastrointestinal tract, dramatically improving bioavailability. SEDDS formulations spontaneously form nanoemulsions upon contact with gastrointestinal fluids. Several approved HIV protease inhibitors and immunosuppressants rely on lipid-based formulation strategies to achieve adequate oral bioavailability.

The disease areas where delivery innovation is having the greatest impact

Oncology has the longest history with lipid-based delivery, and the unmet need remains large. Beyond the approved liposomal cytotoxics, LNP delivery of mRNA cancer vaccines – personalised to encode neoantigens specific to an individual patient’s tumour – is in advanced clinical development. The delivery challenge in oncology is compounded by tumour heterogeneity and the immune microenvironment; the same advances in surface targeting and particle engineering that improve liposome accumulation in tumours are now being applied to LNP systems carrying immunomodulatory RNA payloads.

Rare genetic diseases represent perhaps the clearest demonstration of what delivery technology enables. For conditions caused by loss-of-function mutations – where the patient’s cells are not producing a functional protein – mRNA delivery offers a path to protein replacement that does not require permanent genome editing. The therapeutic effect of a single administration is transient, but repeated dosing can maintain therapeutic protein levels. LNP delivery to the liver is particularly well-established, making hepatic protein deficiencies an accessible first indication class. Conditions being investigated include haemophilia, alpha-1 antitrypsin deficiency, and phenylketonuria.

Infectious disease and vaccines have been transformed by the COVID-19 mRNA vaccine experience. The platform is now being applied to influenza, respiratory syncytial virus (RSV), HIV, cytomegalovirus, and a range of emerging pathogens. The speed advantage of mRNA vaccine development – the ability to update the encoded antigen in weeks rather than months – makes LNP-delivered mRNA vaccines particularly valuable for pandemic preparedness and for pathogens with rapidly evolving surface proteins.

Central nervous system diseases represent the most challenging frontier for drug delivery. The blood-brain barrier excludes the vast majority of systemically administered therapeutics. LNP engineering for CNS targeting – through surface modification with transferrin receptor ligands, apolipoprotein E, or other brain-penetrating motifs – is an active research area with significant implications for conditions including Alzheimer’s disease, Parkinson’s disease, and brain tumours. Intrathecal and intranasal administration routes are also being explored as ways to bypass the blood-brain barrier entirely.

The role of CDMOs in translating delivery science to clinical reality

The advances described above do not translate automatically from academic research to clinical application. They require manufacturing infrastructure, analytical capability, regulatory expertise, and the ability to scale formulations reliably from laboratory quantities to clinical batch sizes – without losing the properties that made the formulation work in the first place.

This is why the contract development and manufacturing organisation (CDMO) ecosystem has become central to drug delivery innovation. Most biotech companies developing RNA therapeutics or novel lipid-based systems do not have in-house LNP formulation expertise, cGMP manufacturing capacity, or the analytical infrastructure to characterise complex nanoparticle systems for regulatory submission. They depend on external partners who have invested in these capabilities.

The scientific depth required is substantial. LNP formulation development demands expertise in ionisable lipid chemistry, microfluidic and extrusion manufacturing processes, particle characterisation by DLS, NTA, and cryo-TEM, and a detailed understanding of how formulation parameters affect in vivo performance. For RNA-based products specifically, the quality of the RNA payload and the integrity of the delivery system are inseparable: a well-formulated LNP built around degraded mRNA will not work, regardless of how precisely the lipid ratios are controlled.

SyVento BioTech represents the kind of integrated CDMO capability that makes translational development possible for organisations without in-house infrastructure. Their platform spans RNA synthesis, lipid-based formulation development across all major system types (liposomes, LNPs, SLN, NLC, nanoemulsions, SEDDS), analytical services aligned with QbD and ICH guidelines, scale-up from lab to 50-litre batches, and aseptic fill and finish – with a research team that is entirely PhD-level in life sciences. The ability to manage the interface between RNA quality and LNP formulation under one roof is particularly relevant for the RNA therapeutics programs that now represent a large and growing share of the drug delivery development pipeline.

What the next decade looks like

The trajectory of drug delivery science points toward increasing specificity, increasing potency, and decreasing systemic exposure. The same LNP platform that today delivers mRNA to hepatocytes is being engineered to deliver to T cells, macrophages, and eventually neurons. The same targeting chemistry that attaches antibodies to liposome surfaces is being applied at nanoscale precision to achieve single-cell-type selectivity.

Simultaneously, manufacturing and analytical technology is catching up with formulation science. Microfluidic manufacturing at commercial scale, continuous manufacturing processes for LNPs, and increasingly sophisticated real-time analytical monitoring are all reducing the variability that has historically been a challenge in nanoparticle production.

The regulatory framework is also evolving. FDA and EMA guidance on nanoparticle characterisation, on the use of platform technology approaches to reduce the regulatory burden for related formulations, and on expedited pathways for RNA-based therapeutics in serious diseases are all making the development path clearer than it was a decade ago.

The result is a field that is simultaneously producing near-term clinical impact – in oncology, rare diseases, and infectious disease – and building the technical foundation for therapeutic approaches that do not yet exist in clinical practice. Drug delivery systems are not changing the way we treat disease only at the margins. For a growing set of diseases, they are the reason treatment is possible at all.